Plasma microRNA signatures to predict EGFR-TKI resistance in EGFR-mutant advanced NSCLC patients.

被引：0
|
作者：
Wang, Shuhang
Wang, Jie
Bai, Hua
An, Tongtong
Zhao, Jun
Wang, Zhijie
Duan, Jianchun
Zhuo, Minglei
Wang, Yuyan
Wu, Meina
机构：
[1] Beijing Canc Hosp, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[2] Peking Univ, Canc Hosp, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
[3] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19136
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Association between EGFR-TKI Resistance and Efficacy of Radiotherapy for Brain Metastases from EGFR-mutant Lung Adenocarcinoma
    Hirata, Hidenari
    Nakamura, Katsumasa
    Kunitake, Naonobu
    Shioyama, Yoshiyuki
    Sasaki, Tomonari
    Ohga, Saiji
    Nonoshita, Takeshi
    Yoshitake, Tadamasa
    Asai, Kaori
    Inoue, Kouji
    Nagashima, Akira
    Ono, Minoru
    Honda, Hiroshi
    [J]. ANTICANCER RESEARCH, 2013, 33 (04) : 1649 - 1655
  • [42] Management of patients with resistance to EGFR-TKI
    Barlesi, F.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2011, 67 : S30 - S35
  • [43] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
    D. Zheng
    X. Ye
    M. Z. Zhang
    Y. Sun
    J. Y. Wang
    J. Ni
    H. P. Zhang
    L. Zhang
    J. Luo
    J. Zhang
    L. Tang
    B. Su
    G. Chen
    G. Zhu
    Y. Gu
    J. F. Xu
    [J]. Scientific Reports, 6
  • [44] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
    Zheng, D.
    Ye, X.
    Zhang, M. Z.
    Sun, Y.
    Wang, J. Y.
    Ni, J.
    Zhang, H. P.
    Zhang, L.
    Luo, J.
    Zhang, J.
    Tang, L.
    Su, B.
    Chen, G.
    Zhu, G.
    Gu, Y.
    Xu, J. F.
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [45] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
  • [46] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    [J]. CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [47] CYTOPLASMIC ERBEXPRESSION PREDICTS POORLY EFFICACY AND SURVIVAL OF EGFR-TKI IN EGFR MUTANT NSCLC
    Wang, Zhijie
    Li, Zhenxiang
    Bai, Hua
    Wang, Jie
    Zhao, Jun
    Wu, Meina
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S354 - S354
  • [48] Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters
    Estevinho, F.
    Felizardo, M.
    Fernandes, G.
    Figueiredo, A.
    Lopes, A.
    [J]. PULMONOLOGY, 2019, 25 (05): : 306 - 309
  • [49] Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
    Tseng, Jeng-Sen
    Hsu, Kuo-Hsuan
    Zheng, Zhe-Rong
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Huang, Yen-Hsiang
    Su, Kang-Yi
    Yu, Sung-Liang
    Chang, Gee-Chen
    [J]. ONCOLOGY, 2021, 99 (01) : 32 - 40
  • [50] The first- or second-line use of pemetrexed sequentially with EGFR-TKI did not differ in PFS for advanced NSCLC patients harboring EGFR-mutant tumors.
    Ding, Zhen-Yu
    Chen, Yue-Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345